Arginine is considered a semi-essential amino acid because even though the body normally makes enough of it, supplementation is sometimes needed. For example, people with protein malnutrition, excessive ammonia production, excessive lysine intake, burns, infections, peritoneal dialysis, rapid growth, urea synthesis disorders, or sepsis may not have enough arginine. Symptoms of arginine deficiency include poor wound healing, hair loss, skin rash, constipation, and fatty liver.
Arginine changes into nitric oxide, which causes blood vessel relaxation (vasodilation). Early evidence suggests that arginine may help treat medical conditions that improve with vasodilation, such as chest pain, clogged arteries (called atherosclerosis), coronary artery disease, erectile dysfunction, heart failure, intermittent claudication/peripheral vascular disease, and blood vessel swelling that causes headaches (vascular headaches). Arginine also triggers the body to make protein and has been studied for wound healing, bodybuilding, enhancement of sperm production (spermatogenesis), and prevention of wasting in people with critical illnesses.
Arginine hydrochloride has a high chloride content and has been used to treat metabolic alkalosis. This use should be under the supervision of a qualified healthcare professional.
A recent study assessed the mechanism by which SARS-CoV-2 Omicron and Alpha VOCs inhibit the SARS-CoV-2 spike protein and mitigate the risk of a multisystem inflammatory syndrome in children.
Athletes and the general population alike train to promote health and physical fitness. With repeated exposure to the minimal stress of exercise, the body adapts.
Researchers examined how SARS-CoV-2 variants of concern differentially use an additional metalloproteinase-dependent entry pathway to enter the host cells.
Autoimmune diseases are triggered when the immune system malfunctions and attacks the body's own structures.
A recent study reported the abrogation of inhibition of the NK cells by a SARS-CoV-2-encoded protein presented by HLA-E.
A study recently accepted for publication in The Journal of Clinical Investigation describes a new and effective therapy to treat glioblastoma: the concomitant use of ADI-PEG20 together with focal brain radiotherapy.
A new study explains how SARS-CoV-2 adapts its immunogenicity to the immune response of the host.
A recently published paper in the journal Molecular Cancer by the group of Dr. Manel Esteller, Director of the Josep Carreras Leukaemia Research Institute, ICREA Research Professor and Genetics Chairman at the University of Barcelona, shows that transfer RNAs for certain amino acids are altered at the epigenetic level in some types of cancer, expressing it in an exaggerated manner in some cases and being deficient in others.
A new study was based on the hypothesis that competitively inhibiting cellular furin and selectively targeting SARS-CoV-2 in the infected viral-producing cells is critical for therapeutic specificity.
A new dietary tool to quickly and accurately assess micronutrient levels aims to help cancer patients fight disease, paving the way to find better nutritional solutions for oncology services, Flinders University researchers say.
A new dietary tool to quickly and accurately assess micronutrient levels aims to help cancer patients fight disease, paving the way to find better nutritional solutions for oncology services, Flinders University researchers say.
Researchers evaluate how the D614G and P681H mutations alter the attributes of SARS-CoV-2 VOCs.
Researchers from China summarized the representative structures of SARS-CoV-2 proteins and discussed the development of novel therapeutic agents for targeting these proteins to treat and prevent COVID-19.
A new paper in the journal Molecules describes this in molecular terms, comparing SARS-CoV-2 with an earlier highly pathogenic coronavirus, SARS-CoV.
A new study discusses the importance of single nucleotide polymorphisms in the Rab46 gene as a marker of adverse outcomes in high-risk COVID-19 patients.
A new study suggests that coronaviruses such as SARS-CoV-2 depend on a furin cleavage site between the S1/S2 subunits to enhance viral infectivity.
A new analysis parses out what scientists currently know about the Delta variant and predicts what the end of the COVID-19 pandemic might look like.
An investigational cancer drug that starves tumors of their energy supply also shows evidence of improving whole body metabolism, according to a new study in mice from Washington University School of Medicine in St. Louis.
A new international study offers a clearer picture of the impact of COVID-19 infection and the risk of severe outcomes on young people around the world.
Researchers conducted a computational analysis of the furin cleavage domain (FCD) of SARS-CoV-2 and its variants, as well as several other viruses.